{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:00:34Z","timestamp":1780473634256,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41375-026-02915-4","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:12:58Z","timestamp":1774339978000},"page":"1176-1188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting UHRF1 induces regression of aggressive mantle cell lymphoma"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1530-6511","authenticated-orcid":false,"given":"Yuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-795X","authenticated-orcid":false,"given":"Zengwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-3389","authenticated-orcid":false,"given":"Weilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-2489","authenticated-orcid":false,"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2915_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","volume":"21","author":"AD Zelenetz","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, et al. NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023. J Natl Compr Canc Netw. 2023;21:1118\u201331.","journal-title":"J Natl Compr Canc Netw"},{"key":"2915_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1182\/blood.2023022352","volume":"145","author":"CE Ryan","year":"2025","unstructured":"Ryan CE, Armand P, LaCasce AS. Frontline management of mantle cell lymphoma. Blood. 2025;145:663\u201372.","journal-title":"Blood"},{"key":"2915_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023022353","volume":"145","author":"E Silkenstedt","year":"2025","unstructured":"Silkenstedt E, Dreyling M. Treatment of relapsed\/refractory MCL. Blood. 2025;145:673\u201382.","journal-title":"Blood"},{"key":"2915_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022;386:2495\u2013506.","journal-title":"N Engl J Med"},{"key":"2915_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2482013","volume":"57","author":"Y Yang","year":"2025","unstructured":"Yang Y, Yang P, Zhang W, Liu H, Sun X, Xiao X, et al. Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study. Ann Med. 2025;57:2482013.","journal-title":"Ann Med"},{"key":"2915_CR6","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1002\/cam4.6009","volume":"12","author":"P Yang","year":"2023","unstructured":"Yang P, Cai QQ, Zhang W, Liu SZ, Liu H, Sun XH, et al. Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis. Cancer Med. 2023;12:13204\u201316.","journal-title":"Cancer Med"},{"key":"2915_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100397","volume":"37","author":"S Loghavi","year":"2024","unstructured":"Loghavi S, Kanagal-Shamanna R, Khoury JD, Medeiros LJ, Naresh KN, Nejati R, et al. Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissue: myeloid neoplasms. Mod Pathol. 2024;37:100397.","journal-title":"Mod Pathol"},{"key":"2915_CR8","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u2013306.","journal-title":"Lancet"},{"key":"2915_CR9","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022;132:e153283."},{"key":"2915_CR10","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","volume":"38","author":"M Khouja","year":"2024","unstructured":"Khouja M, Jiang L, Pal K, Stewart PJ, Regmi B, Schwarz M, et al. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials. Leukemia. 2024;38:2675\u201384.","journal-title":"Leukemia"},{"key":"2915_CR11","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4:2927\u201338.","journal-title":"Blood Adv"},{"key":"2915_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood.2019002385","volume":"136","author":"P Pararajalingam","year":"2020","unstructured":"Pararajalingam P, Coyle KM, Arthur SE, Thomas N, Alcaide M, Meissner B, et al. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020;136:572\u201384.","journal-title":"Blood"},{"key":"2915_CR13","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","volume":"105","author":"S Ferrero","year":"2020","unstructured":"Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604\u201312.","journal-title":"Haematologica"},{"key":"2915_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood.2023022354","volume":"145","author":"P Jain","year":"2025","unstructured":"Jain P, Wang M. High-risk MCL: recognition and treatment. Blood. 2025;145:683\u201395.","journal-title":"Blood"},{"key":"2915_CR15","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","volume":"10","author":"TE Lew","year":"2023","unstructured":"Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10:e142\u2013e154.","journal-title":"Lancet Haematol"},{"key":"2915_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1182\/blood.2024025021","volume":"144","author":"DS Wallace","year":"2024","unstructured":"Wallace DS, Barr PM. Ready, AIM, stop: ibrutinib plus venetoclax in MCL. Blood. 2024;144:800\u20132.","journal-title":"Blood"},{"key":"2915_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ajh.27650","volume":"100","author":"G Lazarian","year":"2025","unstructured":"Lazarian G, Chemali L, Bensalah M, Zindel C, Lefebvre V, Thieblemont C, et al. TP53 mutations detected by NGS are a major clinical risk factor for stratifying mantle cell lymphoma. Am J Hematol. 2025;100:933\u20136.","journal-title":"Am J Hematol"},{"key":"2915_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.semcancer.2019.03.004","volume":"67","author":"D Grimm","year":"2020","unstructured":"Grimm D, Bauer J, Wise P, Kr\u00fcger M, Simonsen U, Wehland M, et al. The role of SOX family members in solid tumours and metastasis. SDin Cancer Biol. 2020;67:122\u201353.","journal-title":"SDin Cancer Biol"},{"key":"2915_CR19","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood.2023022241","volume":"143","author":"MH Abdelrazak Morsy","year":"2024","unstructured":"Abdelrazak Morsy MH, Lilienthal I, Lord M, Merrien M, Wasik AM, Sureda-G\u00f3mez M, et al. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma. Blood. 2024;143:1953\u201364.","journal-title":"Blood"},{"key":"2915_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/blood.2023023242","volume":"144","author":"M Sureda-G\u00f3mez","year":"2024","unstructured":"Sureda-G\u00f3mez M, Iaccarino I, De Bol\u00f2s A, Meyer M, Balsas P, Richter J, et al. SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features. Blood. 2024;144:187\u2013200.","journal-title":"Blood"},{"key":"2915_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2020.06.015","volume":"67","author":"SM Tsang","year":"2020","unstructured":"Tsang SM, Oliemuller E, Howard BA. Regulatory roles for SOX11 in development, stem cells and cancer. SDin Cancer Biol. 2020;67:3\u201311.","journal-title":"SDin Cancer Biol"},{"key":"2915_CR22","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1182\/blood.2020010527","volume":"138","author":"P Balsas","year":"2021","unstructured":"Balsas P, Veloza L, Clot G, Sureda-G\u00f3mez M, Rodr\u00edguez ML, Masaoutis C, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138:2202\u201315.","journal-title":"Blood"},{"key":"2915_CR23","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","volume":"121","author":"MC Vegliante","year":"2013","unstructured":"Vegliante MC, Palomero J, P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Castellano G, Navarro A, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121:2175\u201385.","journal-title":"Blood"},{"key":"2915_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41375-022-01776-x","volume":"37","author":"M Sureda-G\u00f3mez","year":"2023","unstructured":"Sureda-G\u00f3mez M, Balsas P, Rodr\u00edguez ML, Nadeu F, De Bol\u00f2s A, Eguileor \u00c1, et al. Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma. Leukemia. 2023;37:408\u201321.","journal-title":"Leukemia"},{"key":"2915_CR25","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-20-5039","volume":"27","author":"SS Jatiani","year":"2021","unstructured":"Jatiani SS, Christie S, Leshchenko VV, Jain R, Kapoor A, Bisignano P, et al. SOX11 inhibitors are cytotoxic in mantle cell lymphoma. Clin Cancer Res. 2021;27:4652\u201363.","journal-title":"Clin Cancer Res"},{"key":"2915_CR26","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.3324\/haematol.2016.160374","volume":"102","author":"A Navarro","year":"2017","unstructured":"Navarro A, Clot G, Mart\u00ednez-Trillos A, Pinyol M, Jares P, Gonz\u00e1lez-Farr\u00e9 B, et al. Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica. 2017;102:e360\u2013e363.","journal-title":"Haematologica"},{"key":"2915_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/CIRCULATIONAHA.123.065202","volume":"150","author":"X Guo","year":"2024","unstructured":"Guo X, Zhong J, Zhao Y, Fu Y, Sun LY, Yuan A, et al. LXR\u03b1 promotes abdominal aortic aneurysm formation through UHRF1 epigenetic modification of miR-26b-3p. Circulation. 2024;150:30\u201346.","journal-title":"Circulation"},{"key":"2915_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/nar\/gky975","volume":"47","author":"JY Hahm","year":"2019","unstructured":"Hahm JY, Kim JY, Park JW, Kang JY, Kim KB, Kim SR, et al. Methylation of UHRF1 by SET7 is essential for DNA double-strand break repair. Nucleic Acids Res. 2019;47:184\u201396.","journal-title":"Nucleic Acids Res"},{"key":"2915_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-024-03186-6","volume":"43","author":"J Chen","year":"2024","unstructured":"Chen J, Wang D, Wu G, Xiong F, Liu W, Wang Q, et al. STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A. J Exp Clin Cancer Res. 2024;43:260.","journal-title":"J Exp Clin Cancer Res"},{"key":"2915_CR30","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1126\/science.1147939","volume":"317","author":"M Bostick","year":"2007","unstructured":"Bostick M, Kim JK, Est\u00e8ve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007;317:1760\u20134.","journal-title":"Science"},{"key":"2915_CR31","doi-asserted-by":"crossref","unstructured":"Yao J, Luo Y, Zeng C, He H, Zhang X. UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia. Oncol Rep. 2021;46:131.","DOI":"10.3892\/or.2021.8082"},{"key":"2915_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820947489","volume":"19","author":"M Alhosin","year":"2020","unstructured":"Alhosin M, Razvi SSI, Sheikh RA, Khan JA, Zamzami MA, Choudhry H. Thymoquinone and difluoromethylornithine (DFMO) synergistically induce apoptosis of human acute T lymphoblastic leukemia jurkat cells through the modulation of epigenetic pathways. Technol Cancer Res Treat. 2020;19:1533033820947489.","journal-title":"Technol Cancer Res Treat"},{"key":"2915_CR33","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/hep.31642","volume":"73","author":"L Colyn","year":"2021","unstructured":"Colyn L, B\u00e1rcena-Varela M, \u00c1lvarez-Sola G, Latasa MU, Uriarte I, Santamar\u00eda E, et al. Dual Targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Hepatology. 2021;73:2380\u201396.","journal-title":"Hepatology"},{"key":"2915_CR34","doi-asserted-by":"crossref","unstructured":"Demir S, Razizadeh N, Indersie E, Branchereau S, Cairo S, Kappler R. Targeting G9a\/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma. Hepatol Commun. 2024;8:e0378.","DOI":"10.1097\/HC9.0000000000000378"},{"key":"2915_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/hep.30168","volume":"69","author":"M B\u00e1rcena-Varela","year":"2019","unstructured":"B\u00e1rcena-Varela M, Caruso S, Llerena S, \u00c1lvarez-Sola G, Uriarte I, Latasa MU, et al. Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma. Hepatology. 2019;69:587\u2013603.","journal-title":"Hepatology"},{"key":"2915_CR36","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307\u201316.","journal-title":"Cancer Res"},{"key":"2915_CR37","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","volume":"35","author":"DW Scott","year":"2017","unstructured":"Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35:1668\u201377.","journal-title":"J Clin Oncol"},{"key":"2915_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185\u201397.","journal-title":"Cancer Cell"},{"key":"2915_CR39","doi-asserted-by":"crossref","unstructured":"Tang Z, Yang Y, Chen W, Liang T. Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR\/AKT and Wnt\/\u03b2-catenin signaling. Hepatol Commun. 2023;7:e0204.","DOI":"10.1097\/HC9.0000000000000204"},{"key":"2915_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01413-5","volume":"15","author":"Z Tang","year":"2023","unstructured":"Tang Z, Yang Y, Zhang Q, Liang T. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients. Clin Epigenetics. 2023;15:13.","journal-title":"Clin Epigenetics"},{"key":"2915_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-023-00381-7","volume":"12","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yang P, Wang J, Gao S, Xiao S, Zhang W, et al. p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma. Exp Hematol Oncol. 2023;12:28.","journal-title":"Exp Hematol Oncol"},{"key":"2915_CR42","doi-asserted-by":"crossref","unstructured":"Terranova C, Tang M, Orouji E, Maitituoheti M, Raman A, Amin S, et al. An integrated platform for genome-wide mapping of chromatin states using high-throughput chip-sequencing in tumor tissues. J Vis Exp. 2018;5:56972.","DOI":"10.3791\/56972-v"},{"key":"2915_CR43","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2023.05.031","volume":"79","author":"A Claver\u00eda-Cabello","year":"2023","unstructured":"Claver\u00eda-Cabello A, Herranz JM, Latasa MU, Arechederra M, Uriarte I, Pineda-Lucena A, et al. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. J Hepatol. 2023;79:989\u20131005.","journal-title":"J Hepatol"},{"key":"2915_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ejmech.2016.02.043","volume":"114","author":"V Myrianthopoulos","year":"2016","unstructured":"Myrianthopoulos V, Cartron PF, Liutkevi\u010di\u016bt\u0117 Z, Klima\u0161auskas S, Matulis D, Bronner C, et al. Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation. Eur J Med Chem. 2016;114:390\u20136.","journal-title":"Eur J Med Chem"},{"key":"2915_CR45","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41422-022-00735-6","volume":"32","author":"CL Hu","year":"2022","unstructured":"Hu CL, Chen BY, Li Z, Yang T, Xu CH, Yang R, et al. Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia. Cell Res. 2022;32:1105\u201323.","journal-title":"Cell Res"},{"key":"2915_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13046-024-03268-5","volume":"44","author":"D Oyon","year":"2025","unstructured":"Oyon D, Lopez-Pascual A, Castello-Uribe B, Uriarte I, Orsi G, Llorente S, et al. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2025;44:13.","journal-title":"J Exp Clin Cancer Res"},{"key":"2915_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/gutjnl-2019-320205","volume":"70","author":"M Barcena-Varela","year":"2021","unstructured":"Barcena-Varela M, Paish H, Alvarez L, Uriarte I, Latasa MU, Santamaria E, et al. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. Gut. 2021;70:388\u2013400.","journal-title":"Gut"},{"key":"2915_CR48","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1074\/jbc.M112.415398","volume":"288","author":"J Cheng","year":"2013","unstructured":"Cheng J, Yang Y, Fang J, Xiao J, Zhu T, Chen F, et al. Structural insight into coordinated recognition of trimethylated histone H3 lysine 9 (H3K9me3) by the plant homeodomain (PHD) and tandem tudor domain (TTD) of UHRF1 (ubiquitin-like, containing PHD and RING finger domains, 1) protein. J Biol Chem. 2013;288:1329\u201339.","journal-title":"J Biol Chem"},{"key":"2915_CR49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm4043","volume":"16","author":"J Du","year":"2015","unstructured":"Du J, Johnson LM, Jacobsen SE, Patel DJ. DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol. 2015;16:519\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2915_CR50","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/gutjnl-2015-311292","volume":"65","author":"T Hardy","year":"2016","unstructured":"Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics. Gut. 2016;65:1895\u2013905.","journal-title":"Gut"},{"key":"2915_CR51","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2347757","volume":"16","author":"J Su","year":"2024","unstructured":"Su J, Lin X, Li D, Yang C, Lv S, Chen X, et al. Prevotella copri exhausts intrinsic indole-3-pyruvic acid in the host to promote breast cancer progression: inactivation of AMPK via UHRF1-mediated negative regulation. Gut Microbes. 2024;16:2347757.","journal-title":"Gut Microbes"},{"key":"2915_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47314-4","volume":"15","author":"K Yamaguchi","year":"2024","unstructured":"Yamaguchi K, Chen X, Rodgers B, Miura F, Bashtrykov P, Bonhomme F, et al. Non-canonical functions of UHRF1 maintain DNA methylation homeostasis in cancer cells. Nat Commun. 2024;15:2960.","journal-title":"Nat Commun"},{"key":"2915_CR53","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molcel.2024.11.009","volume":"85","author":"Y Liu","year":"2025","unstructured":"Liu Y, Hrit JA, Chomiak AA, Stransky S, Hoffman JR, Tiedemann RL, et al. DNA hypomethylation promotes UHRF1-and SUV39H1\/H2-dependent crosstalk between H3K18ub and H3K9me3 to reinforce heterochromatin states. Mol Cell. 2025;85:394\u2013412.e12.","journal-title":"Mol Cell"},{"key":"2915_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07532-0","volume":"16","author":"Y Huang","year":"2025","unstructured":"Huang Y, Luo L, Xu Y, Li J, Wu Z, Zhao C, et al. UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia. Cell Death Dis. 2025;16:351.","journal-title":"Cell Death Dis"},{"key":"2915_CR55","doi-asserted-by":"crossref","unstructured":"Li X, Fan D, Li Y, Yuan J, Sun W, Zhu Q, et al. NKX2-5\/LHX1 and UHRF1 Establishing a positive feedback regulatory circuitry drives esophageal squamous cell carcinoma through epigenetic dysregulation. Adv Sci (Weinh). 2025;12:e2413508.","DOI":"10.1002\/advs.202413508"},{"key":"2915_CR56","doi-asserted-by":"publisher","first-page":"13733","DOI":"10.1093\/nar\/gkae1105","volume":"52","author":"RL Tiedemann","year":"2024","unstructured":"Tiedemann RL, Hrit J, Du Q, WiSDan AK, Eden HE, Dickson BM, et al. UHRF1 ubiquitin ligase activity supports the maintenance of low-density CpG methylation. Nucleic Acids Res. 2024;52:13733\u201356.","journal-title":"Nucleic Acids Res"},{"key":"2915_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15424","volume":"8","author":"E San Jos\u00e9-En\u00e9riz","year":"2017","unstructured":"San Jos\u00e9-En\u00e9riz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017;8:15424.","journal-title":"Nat Commun"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02915-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:14Z","timestamp":1780470194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02915-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2915"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02915-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Peking University Third Hospital (M2024303), and all the participants signed informed consent. The animal experiment was approved by the Laboratory Animal Welfare Ethics Committee of Peking University Health Science Center (DLASBD0565).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}